P50CA272390

DF/HCC Prostate SPORE - Project Summary – Overall

The Dana-Farber/Harvard Cancer Center (DF/HCC) Prostate SPORE seeks to improve the understanding and treatment of prostate cancer using a highly translational approach. The application consists of three projects, three cores, a developmental research program, and a career enhancement program.

The SPORE infrastructure will facilitate interactions and collaboration within our thriving community of basic, clinical, and population science researchers dedicated to prostate cancer research. Each project addresses a fundamental challenge that contributes to prostate cancer morbidity and mortality.

Project 1 leverages tumor specimens from patients with high-risk prostate cancer treated with neoadjuvant therapies to understand how tumors respond and resist acute potent androgen receptor blockade. It aims to develop novel strategies to improve cure rates and combat resistance.

Project 2 will develop innovative strategies to target the epigenome in later stages of advanced castration-resistant prostate cancer. It will also develop a first-in-field clinical trial focused on co-targeting EZH2 and PARP.

Project 3 delves deep into biomarkers in localized prostate cancer, leveraging innovations in computation and biologically-guided deep learning. Its goal is to deliver precision cancer medicine in this disease state. Understanding why some localized prostate cancers are phenotypically aggressive and predicting which localized prostate cancers will behave in this manner addresses a large clinical unmet need.

Each of these projects combines elegant preclinical work with innovative clinical studies led by DF/HCC investigators.

Core A, the Administrative Core, will be the center for scientific, fiscal, and administrative oversight. It will lead efforts in planning and communication and also house the Patient Advocacy Committee. Core A will ensure that the DF/HCC infrastructure supports the SPORE clinical and translational research efforts.

Core B, the Biostatistics and Computational Biology Core, will provide specialized expertise in biostatistics and the management of genomic and other next-generation sequencing data and data sharing.

Core C, the Biospecimen and Pathology Core, will maintain tissue/blood repositories for the SPORE projects as well as other investigators within the prostate cancer program. It will provide critical expertise and pathology services, including next-generation molecular assays. It will also help facilitate the use of fresh tumor specimens, including rapid autopsies for patient-derived model development, to accelerate translational investigation.

The Developmental Research and Career Enhancement Programs will identify and fund innovative projects that address basic, translational, and clinical research questions and unmet needs in prostate cancer. These programs will support early career and new prostate cancer investigators. They will actively recruit and retain researchers from diverse backgrounds to foster cutting-edge and impactful prostate cancer translational science.

We anticipate that the DF/HCC Prostate SPORE will make substantial scientific discoveries in the field and translate directly into benefits for men with prostate cancer.

Dana-Farber Cancer Institute

NOT APPLICABLE

93.397 - Cancer Centers Support Grants

National Cancer Institute (NCI) [HHS - NIH]

Boston, Massachusetts 022155418 United States

Single Zip Code

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required) (PAR-20-305)

Amendment Since initial award the total obligations have increased 93% from $2,585,567 to $4,979,457.